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Prescription drug misuse affects several million people and results in direct medical costs 
for treatment of patients and indirect costs for society that total billions of dollars per 
year.  Most prescription drug misuse is detected after it has occurred (ex post) by law 
enforcement agencies working with the medical provider community.  The current 
method for enforcement is a litigation approach requiring casework and criminal 
prosecution.  An alternative regulatory mechanism is to use health insurance claims data 
ex ante and expert systems/doctors/economists (specialist enforcers) to screen cases and 
prevent the prescription destined to be misused from being filled.  This paper uses a large 
employer population’s claims data to identify a regulatory approach that might work 
using existing algorithms to detect ex post misuse.  This method shows that up to 1% of 
the covered lives in the employer’s population may be associated with prescription drug 
misuse of controlled substances.  The paper shows key factors that could be used to 
identify patient characteristics associated with misuse.  These key factors can then be 
used in an ex ante predictive model to take a regulatory approach.  The paper concludes 
with a discussion of how point-of-service fraud detection and intervention systems used 
by banks and credit card vendors could be adapted to institute a more preventive ex ante 
regulatory mechanism to stop the actual provision of medication intended for misuse. 
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Introduction 
  The misuse of prescription drugs in the Unites States is a growing problem.  Rates 
of prescription drug misuse in the United States have risen significantly during recent 
years, with one study reporting an increase of 2.5 million prescription drug misusers 
between 2002 and 2007
i.  The issue is not contained to the United States.  A recent report 
from the UK’s National Institute for Clinical Effectiveness (NICE) estimates that 280,000 
Britons are abusing prescription opioids.
ii  This represents just under half of one percent 
of the UK’s general population under the age of 65.  The issue is complex because of the 
many agents engaged in the provision of prescription medications, as well as the 
regulations placed on the prescribing agents.  Beyond the first party patient and the 
supplier of the prescription, there is the second party physician who prescribed the 
medication, followed by the third party public or private insurance company who 
financed the drug, and the fourth party prescription benefit management firm setting the 
price for the drug.  Complicating matters further, insurance claims data provide an 
electronic trace of the entire set of transactions that could demonstrate misuse ex post. 
The complication stems from the fact that ex post measurement using electronic point-of-
sale transaction data suggests that an ex ante regulatory approach might have limited the 
scope of the problem, had agents two, three and four used the available technology.  
                                                 
i Substance Abuse & Mental Health Services Administration (SAMHSA). (2007). Results 
from the 2006 National Survey on Drug Use and Health. Rockville, MD: Office of 
Applied Studies.; McCabe, S. E., West, B. T., & Wechsler, H. (2007). Trends and 
college-level characteristics associated with the non-medical use of prescription drugs 
among US college students from 1993 to 2001. Addiction, 102(3), 455-465. 
 
ii See: http://www.nice.org.uk/CG51   2
  This paper presents an exploratory analysis of the extent to which prescription 
drug abuse for pain medication could be identified prospectively for intervention by 
health insurers, supported by law enforcement and the medical community.  The paper 
proceeds first with a general distinction between misuse and abuse, and how its remedy 
would be considered in the insurance contract.  The second part of the paper describes the 
current ex post process for detection after it has occurred by police and law enforcement.  
The third part presents an ex ante alternative to the ex post "litigation" approach.  This 
alternative approach applies expert systems designed by 
doctors/pharmacists/statisticians/law enforcement/economists to insurance claims data in 
order to screen high probability misuse for intervention and education.  The fourth 
section demonstrates how this “regulation” approach might work using the application of 
a published algorithm.  The paper concludes with a discussion of how this might work as 
a regulatory approach, either in the hands of law enforcement or private health plans. 
Misuse versus Abuse 
When considering the prospect of drug misuse, the question of whether or not 
drug abuse has occurred is confusing and warrants attention.  One of the clearest 
distinctions between abuse and misuse comes from the American Medical Association's 
Committee on Alcoholism and Addiction’s 1966 definition where abuse of stimulants 
(amphetamines, primarily) was defined in terms of 'medical supervision'.  Specifically, 
the Committee stated:
iii 
“'Use' refers to the proper place of stimulants in medical practice; 'misuse' applies 
to the physician's role in initiating a potentially dangerous course of therapy; and 
                                                 
iii See: http://jama.ama-assn.org/cgi/content/abstract/268/8/1012 
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'abuse' refers to self-administration of these drugs without medical supervision 
and particularly in large doses that may lead to psychological dependency, 
tolerance and abnormal behavior.” 
In this paper, we will measure both the misuse and abuse of prescribed controlled 
substances with an understanding that both terms can apply.  Misuse will be used as the 
principal concern, since the medications considered are, at least in the United States, only 
obtainable through a physician prescription.  This process automatically involves the 
physician, whether willfully giving a potential abuser a stimulant or being deceived by a 
patient who presents a false medical need (e.g., severe pain from a sprain with no easy 
way to verify physical evidence that indicates damage to the patient).  NICE posits a 
more contemporary definition of misuse defined as:
iv 
“Intoxication by – or regular excessive consumption of and/or dependence on 
– psychoactive substances, leading to social, psychological, physical or legal 
problems. It includes problematic use of both legal and illegal drugs (including 
alcohol when used in combination with other substances).” 
This definition of misuse suggests that the physician must be playing a role in the 
prescribing of controlled substances.  Furthermore, it emphasizes the societal costs of 
misuse of controlled substances and why law enforcement agencies seek to mitigate and 
prevent the inappropriate use of these prescribed medications. 
The Problem of Controlled Substance Misuse 
   The diversion, abuse, and inappropriate use of controlled substances are subjects 
of continuing concern to law enforcement, the medical community, insurers, and policy 
                                                 
iv See: http://www.nice.org.uk/CG51   4
makers alike. These parties seek a balance between preventing diversion/abuse and 
encouraging the use of controlled substances for legitimate medical need, particularly for 
pain management.
1-3 A number of clinical practice guidelines, consensus statements from 
professional associations, and state laws and policies emphasize that it is essential for 
opioid analgesics to be available for the treatment of moderate to severe pain, and that 
prescribing should be individualized to the patient. 
2,4-14 Although some progress has been 
made in treating pain, under-treatment of pain is still prevalent.
15-17 
  Media coverage of diversion and abuse of controlled substances, as well as 
uncertainty regarding potential disciplinary action, may cause physicians to hesitate when 
considering treatment for a patient who could require long-term or high doses of opioids.  
This is exacerbated when physicians have trouble discerning between a patient with a 
legitimate pain problem and one who is feigning pain to obtain drugs for abuse or 
diversion.
18 Because pain is subjective and cannot be measured or ruled out by laboratory 
tests or physical examination, physicians rely largely on their interpretation of patient 
interviews and histories to determine a patient’s need for analgesics.  However, they 
often find themselves in the predicament of wanting to treat seemingly legitimate patient 
needs without having information about their patients’ prescription drug and medical 
histories, which would help identify and address any problems.  A 1999 report from the 
Institute of Medicine stressed that most medical errors do not result from individual 
practitioners’ recklessness.  Instead, they can be attributed to faulty processes and 
systems that lead people to make mistakes or fail to prevent them through lack of 
information and support in a complex working environment.
19 Solving problems within 
the healthcare industry requires the design of systems and processes to help avoid errors,   5
to minimize the damage caused by errors that do occur, and to analyze the pattern of 
errors to discover ways to prevent them. 
  Despite technological advances and the wealth of strategic knowledge within 
administrative healthcare claims databases, currently only 17 states operate electronic 
prescription monitoring programs, which vary in their goals, structure, and oversight by 
the health profession.
20-25 Presently, few health plans analyze the data to identify potential 
misuse of controlled substances. Access to this aggregate information on patients is not 
readily provided to physicians, restricting their ability to provide quality care. In response 
to this need, we developed a software program that identifies patients with potential 
prescription mismanagement or abuse/diversion issues. 
Comparing Ex Post Litigation versus Ex Ante Regulation of Drug Misuse 
  In the last two decades, many public policy initiatives have been started to 
mitigate the misuse of controlled substances through education programs in schools and 
communities.  Despite this emphasis on prevention, the most likely public policy 
interaction occurs through ex post litigation, where law enforcement officials seek to 
detect and prosecute systematic misuse and diversion schemes.  In these cases, evidence 
of misuse and diversion is used to prosecute the drug users as well as the physician 
prescribers.  This ex post litigation approach is expensive, and it is difficult to show its 
impact beyond media coverage of exceptional cases.   
  In contrast, an ex ante regulatory approach to drug misuse would take a more 
comprehensive approach.  It would combine the law enforcement activity with 
surveillance of electronic prescribing systems and interventions to stop or delay 
prescriptions in order to make sure diversion or patient-initiated abuse is not occurring.    6
The intervention process analysis uses the same data available to pharmacists (and some 
physicians) and could succeed in creating an ex ante regulatory system.  Such a system 
would go beyond the current ex post use of electronic data to identify an adverse practice 
pattern for intervention as well as litigation.  To be a truly ex ante system, the electronic 
data would be used in real time to prevent the prescription from being received by the 
abusing or diverting recipient.  This ex ante approach would be more regulatory in nature 
and would have to carefully examine mechanisms to minimize false positives in misuse 
identification.  Failure to do so would create an access-to-care problem for severe pain 
patients with legitimate need for prescribed medication. 
A regulatory approach could also be viewed as a fraud mitigation device.  For 
example, the ex ante risk scoring of credit card transactions at the point of sale to reduce 
fraudulent purchases  is quite analogous to the issue of preventing prescribed medication 
misuse.  Healthcare fraud is a serious and expensive issue in the United States.  The 
National Health Care Anti-Fraud Association (NHCAA) estimates that in calendar year 
2003, at least $51 billion, or 3% of the nation’s annual healthcare outlay, was lost to 
outright fraud. Other estimates by government and law enforcement agencies place the 
loss as high as 10% of our annual expenditure or, in 2009 dollars, $250 billion.
v   In a 
conceptual model of fraud, a fraudulent consumer/potential patient derives no benefit 
from medical care through an improvement in health status.  Fraud activities diminish the 
consumer welfare by providing an additional cost (directly or indirectly) to patient care to 
cover the expense to the consumer or the consumer’s insurer of an unneeded and possibly 
                                                 
v Healthcare Fraud: A Serious and Costly Reality for All Americans, National Health Care Anti-fraud Association, 
http://www.nhcaa.org/pdf/all_about_hcf.pdf site visited on 8/14/2005. 
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fictitious good or service.  Thus, a regulatory mechanism that detects prescribed 
medication misuse can be defined as an activity that uncovers fraud and thereby restores 
societal resources lost to that crime.   
Methods 
  The methods for this analysis have three components.  First, metrics for 
identifying drug misuse are introduced based on a set of existing algorithms.  Second, the 
study population for this analysis is introduced.  Finally, the empirical specification for a 
multivariate analysis to identify the patient level attributes associated with most common 
metrics of abuse is presented.  
Identifying Metrics for Drug Misuse 
   For this analysis, we will use a drug misuse algorithm developed in consultation 
with key experts in the field including a multidisciplinary expert panel consisting of  
addictionists pain physicians, psychologists, psychiatrists, law enforcement officials and 
pain management nurses.  This algorithm, called CS-PURE, published in 2004
vi, 
represents the most comprehensive non-proprietary tool available at present to measure 
drug misuse.  CS-PURE can be applied to claims databases in order to identify possible 
abuse or diversion of controlled substances by patients, or mismanagement by 
prescribers. The CS-PUREs are not conclusive of inappropriate use; rather they aim at 
improving patient safety and outcomes by alerting prescribers and insurers of potential 
problems so that further evaluation can be conducted. The expert panel reached 
consensus on a 38 prototype CS-PURE for evaluation. Some of the CS-PUREs were 
                                                 
vi Parente, S.T., Kim, S., Finch, M., Schloff, L., Rector, T., Seifeldin, R., Haddox, J.D. 
“Using Claims Data to Identify Controlled Substance Patterns of Utilization Requiring 
Evaluation.” American Journal of Managed Care, November 2004; 10(11 Pt 1):783-90.   8
based on similar patterns, but reflected variations in specific medications used and 
changes in the duration of consecutive or overlapping days of medication use; for 
example, continuous overlap of two or more benzodiazepines for at least 30, 60, or 90 
days. 
  Computer programs based on the expert panel’s originally suggested 38 CS-
PURE patterns were developed using SAS, to apply the CS-PURE to the healthcare 
claims data. Detailed utilization profiles were produced for the patients identified by each 
of the prototype CS-PUREs. An interdisciplinary project team, comprised of pharmacists, 
computer programmers, and health services researchers, reviewed and assessed these 
profiles for the accuracy of the computer coding.  At the conclusion of this process, the 
original 38 CS-PUREs were reduced to 34 CS-PUREs.  This change reflected the 
deletion of four of the original CS-PUREs because they identified an extremely low 
number of patients and, thus, determined to be of comparably limited use. 
  Table 1 presents the top 10 metrics of prescribed opioid misuse based on the final 
34 published CS-PUREs.  The top 10 metrics’ distinction was based on an optimal mix of 
period prevalence of the pattern found in the population.  In addition, the percent of 
expert agreement in patient profile review of whether the algorithm truly found a misuse 
case was also considered.  The largest two metrics, measured at the patient level, defined 
as >=6 pharmacies dispensing scripts to a patient for opioids and >=4 physicians 
prescribing controlled substances in a year, constitute .21% and .13% of the health plan’s 
population, respectively.  Law enforcement officials agreed with roughly half of the 
cases.  For two of the other eight remaining metrics, law enforcement agreed with 100% 
of the cases, presented through claims data alone, that intervention was required.     9
Table 1 – Top 10 Metrics for Prescribed Opioid Misuse  
Overall Clinical Legal
1
Multiple prescribers (≥6 prescribers for same 
drug) 0.21% 55% 59% 48% 60% 59%
2
Multiple pharmacies (≥4 different pharmacies for 
same drug) 0.13% 59% 64% 51% 64% 64%
3
Chronic use of (≥4 prescriptions in 6 months) carisoprodol
0.13% 64% 68% 58% 68% 71%
4
Continuous overlap of ≥2 different benzodiazepines for ≥30 
days, when 1 is for alprazolam 0.06% 56% 58% 50% 56% 55%
5
Estimated ≥4 g of acetaminophen/day
0.03% 100% 100% 100% 100% 100%
6
≥2 prescriptions for meperidine with >2 days 
supply
0.02% 100% 100% 100% 100% 100%
7
Chronic use of (≥4 prescriptions in 6 months) butorphanol
0.02% 56% 50% 67% 100% 100%
8
Continuous overlap of ≥2 different benzodiazepines for ≥90 
days, when 1 is for clonazepam 0.01% 63% 67% 54% 65% 63%
9
Continuous overlap of ≥2 different benzodiazepines for ≥90 
days, when 1 is for diazepam 0.00% 63% 65% 60% 60% 60%
10
Overlap of ≥2 different sustained-release or long-acting 
opioids for ≥90 consecutive days 0.00% 63% 67% 50% 69% 69%
Used for Study










  In Figure 1 a national representation of drug-misuse from the  >=4 prescriber 
algorithm shows significant regional heterogeneity with no clear pattern by large regional 
census areas of the Northeast, South or Midwest and West, or urban and rural state 
comparisons.  At the very least, a national representation can help to prioritize resources 
for possible ex ante intervention.  The data presented in Figure 1 are from 2002.  As a 
verification of the algorithm’s potential, the state of Kentucky stands out as a high 
potential drug misuse and diversion state.  This is supported by the July 2002 National 
Drug Intelligence Center report, which stated  that from 1998 through 2000, treatment for 
the abuse of prescription drugs accounted for 20 percent of all treatment admissions in 
the state, and the number of patients seeking treatment for Oxycodone addiction 
increased 163 percent.
vii  Since that time, Kentucky has installed an electronic prescriber 
early warning system, the Kentucky All Schedule Prescription Electronic Reporting 
                                                 
vii See: http://www.medicalnewstoday.com/articles/135591.php   10
(KASPER), to allow law enforcement officials to monitor controlled substance 
prescriptions dispensed in Kentucky.  
Figure 1 
National Variation in Pain Medication Misuse, 







  For this analysis, we focused on the four substance abuse misuse algorithms.  The 
criteria used for selection were the most prevalent patterns and those where law 
enforcement officials have the greatest agreement for intervention and, thus, support an 
ex ante regulatory mechanism.  These algorithms are used in the empirical analysis 
described below:   11
  Multiple Prescribers (6 or more prescribing physicians) for controlled 
substance in one year. 
  Multiple Pharmacies (4 or more) where controlled substances were received in 
one year. 
  Chronic Use (180+ days four or more grams), Stadol. 
  2+ concurrent scripts for Demerol w/day supply greater than two. 
 
Data Sources 
The data source for the analysis is a large national employer with over 300,000 
covered lives in multiple states.  Both medical and pharmacy claims data for two years 
were available for analysis.  Enrollment data were available as well to ensure that the 
employee or their dependents were enrolled in a health plan for two years to avoid 
omitted variable bias.  The employer’s human resource data also included salary 
information of the contract holder.  The data used in the analysis have a common 
structure, similar to that used by any employer, insurer, or government health insurance 
program such as Medicaid. 
Empirical Approach 
  The empirical approach for this analysis was completed in three steps.  First, the 
CS-PURE algorithms were run for the employer data described above; this provided 
analytic files to generate descriptive statistics and run a bivariate analysis where the 
personal attributes of the population are compared between a group with any CS-PURE 
identification and those without any CS-PURE association.  In the second step, a logistic 
regression analysis was completed to identify the factors most associated with the two 
most prevalent CS-PURE algorithms.  The independent variables used in the regression 
model include:   
  Age (& age-squared) and gender   12
  Primary contract holder (i.e., subscriber) 
  Medicare/retiree contract 
  Out of pocket premium for insurance contract 
  Wage salary 
  Prior year incidence of exceeding consumer cost of insurance (premium 
and pharmacy copayments). 
 
  Beyond the age, gender, and income variables, additional information was 
included to provide a proxy for health risk, as well as prior consumption based the 
previous year’s claims data.  Specifically, the dollar amount of a person’s excess 
expenditure beyond their own cost sharing contribution to the health plan was computed 
for the prior year (2004).  The cost sharing contribution included premium price, 
copayments, deductibles, and coinsurance paid by the employee.  In terms of insurance, a 
positive excess amount would be regarded as a medical loss greater than the insured 
contribution to the health plan.  The expectation was that a patient with a history of health 
problems and a higher level of medical loss in the previous year would be likely to have 
high consumption in a second year.  Also included in the model was whether or not the 
contract was for a Medicare recipient who would have prescription drug coverage 
provided by their employer as well as retiree designation, which could occur before the 
age of 65.  The concurrent out-of-pocket premium was also included to provide a control 
for the generosity of the health plan benefit, which could influence the likelihood 
someone would get a less costly (in terms of reduced cost sharing) prescription, intended 
for misuse or diversion, from their physician. 
  The last part of the empirical modeling was a GLM regression model on the 
overall CS-PURE count.  This approach accounts for the fact that a patient may use   13
multiple methods for drug misuse.  Thus, a positive and significant coefficient would be 
associated with attributes of an individual likely to escalate drug misuse and diversion. 
Results 
 
Table 2 presents the period prevalence of the misuse metrics selected for analysis.  
One thing to note is the significant increase in the prevalence of multiple prescriber and 
multiple pharmacy algorithms compared to the 2004 article where they were first 
reported with a national sample of claims data.  For example, in Table 1, the period 
prevalence for multiple prescribers was 0.21%.  In Table 2, the prevalence has increased 
dramatically to 0.90%.  Just over two percent (2.19%) of the population would be flagged 
for any CS-PURE.  This is also a substantial increase since 2004 when the prevalence of 
any CS-PURE was 0.5%.  With respect to the misuse metrics most identified by law 
enforcement as needing intervention, the prevalence ranged from 0.04% to 0.0089%.  
0.04% of this employer’s population would be 81 individuals a year that could face 
criminal charges for misuse or diversion.  
 




Multiple Prescribers (6 or more prescribing physicians) for controlled 
substance in one year. 0.9024%
Multiple Pharmacies (4 or more) where controlled substances were 
received in one year. 1.6115%
Chronic Use (180+ days 4 or more grams), Stadol 0.0464%
Chronic Use (180 days), Demerol, Brand+generic  0.0207%
2+ concurrent scripts for Demerol w/day supply greater 2.  0.0089%
Any CS-PURE 2.19%
CS_PURE Count 0.03    14
 
  Table 3 shows the results of the bivariate analysis.  Of 202,791 continuously 
enrolled members, over 2%, or 4,431, have any indication of misuse indicated by CS-
PURE metrics chosen for this analysis.  Those who have a misuse flag are younger, are 
associated with a higher earning employee, and are less likely to be the contract holder.  
If not the contract holder, the insured would be the spouse or dependent of the contract 
holder.  Those with less out-of-pocket payments are more likely to have a misuse flag.  
However, if the insured members have expenses greater than the amount paid for the 
insurance contract (including premium and copayments), they were more likely to have 
been flagged.  This may be a cause for concern, as it suggests a serial pattern of fraud and 
misuse.  It also could indicate someone in great pain from a chronic condition who relies 
on multiple pharmacies and prescribers.  Even in the most generous cases, law 
enforcement officials found half of these flagged cases required intervention.  
Table 3 – Attributes of Individuals with any CS-PURE 
Sample Standard Sample Standard  T-test
Variable Description Mean Deviation Mean Deviation
Insured Chararacteristics
Insured age in 2005 52.08 19.28 56.30 21.01 ***
Age squared in 2005 3084.30 1897.92 3611.34 2132.14 ***
Insured is female=1, male=0 62.5% 48.4% 62.0% 48.5%  
Wage Salary ('000s) $42.57 $32.78 $40.54 $34.56 ***
Insured is a primary contract holder=1, else 0 58.6% 49.3% 68.8% 46.3% ***
Medicare/retiree contract=1, else 0 26.0% 43.8% 37.5% 48.4% ***
Out of pocket insurance premium '05 ('000s) $0.69 $1.54 $0.74 $1.47 *
Amount over loss ratio in '04 ('000s) $5.62 $7.27 $2.24 $4.01 ***
Statistical Significance
*** p<=.001, ** p<=.01, *P<=.05
N=198,360 N=4,431
Any CS-PURE Flag No CS-PURE Flag
   15
  Tables 4 and 5 display the logistic regression results of the attributes of a person 
associated with the two most prevalent misuse metrics.  In both tables, the attributes’ 
statistical significance and direction of effect on the probability of misuse are nearly 
identical.  While age is positively associated with misuse, older members have a more 
negative relationship as indicated by age squared term.  Gender and retiree status are not 
significant factors.  Income is negatively associated with misuse for both metrics. Out-of-
pocket premiums have a negative but statistically insignificant association with misuse.  
However, the dollar amount paid in the previous year for insured care beyond the 
consumer’s purchase of the insurance contract that year is positively and significantly 
associated with misuse.  If the insured person is genuinely misusing a controlled 
substance, this suggests a serial behavior and significant opportunity for intervention, 
given that they would have been caught by law enforcement if ex post methods were 
successful.  If ex post methods are used successfully, this person would have been 
caught. 
Table 4 – Logistic Regression Results- >=6 Prescribers 
 Standard  Odds
Variable Description Coefficient Deviation P-value Ratio
Intercept -4.858 0.1219   <.0001
Insured age in 2005 0.064 0.0059   <.0001 1.066
Age squared in 2005 -0.001 0.0001   <.0001 0.999
Insured is female=1, male=0 -0.026 0.0493 0.60 0.975
Wage Salary ('000s) -0.00203 0.000877 0.02 0.998
Insured is a primary contract=1, else 0 -0.5577 0.0516   <.0001 0.572
Medicare/retiree contract=1, else 0 0.1395 0.101 0.17 1.15
Out of pocket insurance premium '05 ('000s) -0.0307 0.0175 0.08 0.97
Amount over loss ratio in '04 ('000s) 0.057 0.003   <.0001 1.059
Observations 202,791    16
Table 5 – Logistic Regression Results- >=4 Pharmacies 
 Standard  Odds
Variable Description Coefficient Deviation P-value Ratio
Intercept -4.430 0.0997   <.0001
Insured age in 2005 0.033 0.0042   <.0001 1.034
Age squared in 2005 0.000 0.0001   <.0001 1.000
Insured is female=1, male=0 0.111 0.0376 0.00 1.117
Wage Salary ('000s) -0.0035 0.000678   <.0001 0.997
Insured is a primary contract=1, else 0 -0.3133 0.0397   <.0001 0.731
Medicare/retiree contract=1, else 0 -0.0829 0.071 0.24 0.92
Out of pocket insurance premium '05 ('000s) 0.00159 0.0124 0.90 1.002
Amount over loss ratio in '04 ('000s) 0.087 0.003   <.0001 1.091
Observations 202,791
 
       Table 6 reports the results of a GLM regression to show the attributes most 
associated with multiple instances of misuse.  This model shows more significant 
relationships with potential fraud/misuse than the metric focused logistic regressions.  
Age remains a significant factor where older, but not too much older, insured individuals 
are more likely to misuse.  There is now a significant and positive relationship associated 
with a female contract holder.  One of the strongest negative relationships is associated 
with non-primary contract holders.  This makes sense because the consequence of being 
discovered misusing drugs would mean more to an employee; they could face job 
termination if caught.  The consequences for a spouse or dependent are less direct and 
explain the negative relationship with primary contract holders.  Income remains a 
negative factor.  The loss ratio metric, however, is quite significant and positive.    17
Table 6 – GLM Regression – CS-PURE Count 
   Standard 
Variable Description Coefficient Deviation T-Stat
Intercept 0.021448 0.002114 10.15
Insured age in 2005 0.000533 0.000085 6.30
Age squared in 2005 -0.000009 0.000001 -9.04
Insured is female=1, male=0 0.003191 0.000837 3.81
Wage Salary ('000s) -0.000039 0.000014 -2.71
Insured is a primary contract=1, else 0 -0.008197 0.000975 -8.40
Medicare/retiree contract=1, else 0 -0.004078 0.001581 -2.58
Out of pocket insurance premium '05 ('000s) 0.000277 0.000279 0.99
Amount over loss ratio in '04 ('000s) 0.005333 0.000099 53.71
Observations 202,791  18
Discussion 
  There are several original findings from this analysis.  With respect to identifying 
patterns that could be used for ex ante regulation of controlled substance misuse, the 
analysis suggests that those likely to misuse are older (but not very much older), low 
wage earners, women, not the primary insurance contract holder, and are expending more 
than the actuarial fair value of an insurance contract.  The analysis also indicates that the 
overall period prevalence for abuse may have increased from 2002 to 2005.  Although it 
is only a first step in developing a predictive model for an ex ante screening algorithm, 
the results show there are some person level attributes that could be strong factors for 
consideration in designing and implementing a regulatory mechanism. 
  From a litigation and regulatory perspective, this analysis demonstrates the 
potential of an ex ante approach that could go beyond programs like Kentucky’s 
KASPER.  This analysis demonstrates that the ex ante approach needs to do more than 
simply monitor prescriptions out the door.  It would need to actually assemble person 
level profiles of drug utilization and update them in real time.  While this would appear to 
be an aggressive step, it does have precedent in retail sector fraud detection and 
prevention systems used by the banking and credit card industries.  In those systems, 
multiple data sources at the consumer level are combined and analyzed at the point of 
sale to suggest an apparent pattern, and to restrict a retail transaction such as the purchase 
of a flat panel TV at a discount electronics store.  Many consumers experience this 
system when they travel out-of-state, use their credit cards to buy gas more than 500 
miles away, and receive challenge questions for their zip code.  Likewise, a consumer 
may be denied until completing a phone call with the credit card company when buying   19
an extraordinary retail purchase.  The technology exists, and this sort of ex ante 
regulatory mechanism could be used for controlled substances misuse prevention.  A 
likely obstacle will be privacy advocates.  However, a small pilot using credit and debit 
card purchases of controlled substances could be undertaken using the existing fraud and 
abuse infrastructure as a regulatory precedent.   
  The analysis has four limitations.  First, the sample used – while large and located 
in several U.S. states – is not sufficiently large enough for a comprehensive analysis.  
This could be addressed with a larger sample from an insurer.  However, the insurer will 
not necessarily have the wage information or the contract information that was helpful in 
identifying a patient level attribute of potential misuse.  A second limitation is that the 
false positive misuse-flagging rate for the two most common metrics is 50%.  While 
better than nothing, it suggests that a completely automated ex ante system would require 
refinement.  Our more specific metrics with 100% law enforcement agreement had 
relatively low prevalence, but would need to be re-tested to make sure the accuracy of the 
metric has not degraded since 2004.  A third limitation is that the algorithms could 
potentially be out of date, since they are based on older national drug codes.  However, 
the therapeutic class based algorithms should be accurate for the more specific metrics.  
Also, not expanding the algorithms to include new prescribed medications/controlled 
substances on sale since 2004 could constitute a more conservative metric of misuse. 
  The final limitation of this analysis is that we can not verify the accuracy of the 
algorithms.  Thus, our results are not conclusive in a fashion similar to ex post case where 
the accused drug mis-user or diverter was found guilty.  Instead, the paper uses an expert 
opinion approach to gather the opinions of clinical and law enforcement that validated a   20
set of cases with respect to their probability of misuse.  While this approach is generally 
accepted approach in clinical research, it would be best to know, through random police 
investigations and ultimately criminal trials, whether a particular series of claims actually 
constituted illegal drug abuse or not.
viii  Unfortunately, this research design is outside the 
scope of this analysis.  It should be noted that the law enforcement officials who 
reviewed the results of the analysis commented several times for egregious cases that 
they wanted the names of those we profiled (we were not at liberty to share) and that they 
wanted to use the results as evidence in a court of law.   
  New electronic health records systems could offer even more opportunities for ex 
ante regulatory mechanisms.  Electronic health record interoperability has tremendous 
potential to coordinate data systems, create more robust misuse surveillance systems, and 
could substantially lower detection costs.
ix  The current CS-PUREs have substantially 
lower costs to identify cases with otherwise labor intensive police detective work through 
the ex post and litigation mechanisms.  Interoperability allows for corroborating the 
validity of online and automated transactions from multiple data sources for any given 
patient in real or near real time.  Interoperability and a demand for cross-entity 
standardization of codes, data structures, and terminologies may be the key to creating 
the necessary incentive for better care practices, including controlled substance 
mitigation.   
                                                 
viii A Delphi approaches are recently gaining acceptance for ex ante law enforcement 
planning.  For example, in a 2009 working paper Zaloom and Subhedar from Lamar 
University are using Delphi methods to prioritize events impacting operations from a possible 
terrorist attack, disasters or failures in the maritime domain. See: 
http://dept.lamar.edu/industrial/Ports/Subhedar_041609_MDP_041709-R4_MDP_060609-
R1.pdf 
ix Brushwood, DB. Maximizing the Value of Electronic Prescription Monitoring  
Programs.  The Journal of Law, Medicine & Ethics Volume 31 Issue 1, Pages 41 – 54, 
Published Online: 24 Jan 2007.   21
  A critical issue to consider is the cost for identification and lack of intervention.  
Following the publication of the CS-PUREs in 2004, the manufacturer of an oxy-codeine 
product encouraged the use of the algorithms to mitigate misuse.  The response from 
health plans was initially positive in 2005 and 2006.  Subsequently, the health plans’ 
implementation of the metrics have been challenged by some of the health plans’ legal 
counsel about the consequences of identifying, but not intervening, and possibly being 
found negligent if an adverse event tied to misuse occurred.  If this is indeed a threat to 
the use of these algorithms, there needs to be some regulatory protection for public and 
private insurers to detect, monitor, and develop (but not yet deploy) cost-effective 
strategies, possibly in consultation and open communication with law enforcement.  If 
such a compact was developed, the best of the litigation and regulatory approaches could 
be combined to address this societal problem. 
 
Conclusion 
  This paper demonstrates the potential of a regulatory mechanism that could be 
used on an ex ante basis to detect drug misuse for future intervention by law enforcement 
officials.  An analysis from a large employer shows the scope of the problem as well as 
the opportunity.  The cost of insurance claims and e-prescribing surveillance is modest 
compared to the human capital expense of detection.  Effective intervention continues to 
carry a substantial cost for controlled substance misuse.  Using electronic data with an 
potentially more efficient but effective ex ante approach to tackle the problem of misuse 
warrants further investigation.   22
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